Molecular diagnosis of hemochromatosis.

Expert opinion on medical diagnostics Pub Date : 2013-03-01 Epub Date: 2013-01-23 DOI:10.1517/17530059.2013.763794
Alberto Piperno
{"title":"Molecular diagnosis of hemochromatosis.","authors":"Alberto Piperno","doi":"10.1517/17530059.2013.763794","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The discovery of hemochromatosis genes and the availability of molecular-genetic tests considerably modified the knowledge of the disease relative to physiopathology, penetrance, and expression, and had major impact in the diagnostic settings.</p><p><strong>Areas covered: </strong>Hemochromatosis is a heterogenous disorder at both genetic and phenotypic level. The review discusses criteria to define patients' iron phenotype and to use molecular tests to diagnose HFE-related and non-HFE hemochromatosis. The material examined includes articles published in the journals covered by PubMed US National Library of Medicine. The author has been working in the field of iron overload diseases for several years and has contributed 18 of the papers cited in the references.</p><p><strong>Expert opinion: </strong>Hemochromatosis genotyping is inseparable from phenotype characterization. A full clinical assessment is needed and DNA test performed when data suggest a clear indication of suspicion of being at risk for HH. HFE testing for p.Cys282Tyr mutation and p.His63Asp variant is the first molecular diagnostic step. Genotyping for rare mutations can be offered to patients with negative first-level HFE testing who have iron overload with no other explanation and should be performed in referral centers for iron overload disorders that can provide genetic advice and in-house genotyping services.</p>","PeriodicalId":72996,"journal":{"name":"Expert opinion on medical diagnostics","volume":"7 2","pages":"161-77"},"PeriodicalIF":0.0000,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1517/17530059.2013.763794","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on medical diagnostics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1517/17530059.2013.763794","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 19

Abstract

Introduction: The discovery of hemochromatosis genes and the availability of molecular-genetic tests considerably modified the knowledge of the disease relative to physiopathology, penetrance, and expression, and had major impact in the diagnostic settings.

Areas covered: Hemochromatosis is a heterogenous disorder at both genetic and phenotypic level. The review discusses criteria to define patients' iron phenotype and to use molecular tests to diagnose HFE-related and non-HFE hemochromatosis. The material examined includes articles published in the journals covered by PubMed US National Library of Medicine. The author has been working in the field of iron overload diseases for several years and has contributed 18 of the papers cited in the references.

Expert opinion: Hemochromatosis genotyping is inseparable from phenotype characterization. A full clinical assessment is needed and DNA test performed when data suggest a clear indication of suspicion of being at risk for HH. HFE testing for p.Cys282Tyr mutation and p.His63Asp variant is the first molecular diagnostic step. Genotyping for rare mutations can be offered to patients with negative first-level HFE testing who have iron overload with no other explanation and should be performed in referral centers for iron overload disorders that can provide genetic advice and in-house genotyping services.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血色素沉着症的分子诊断。
简介:血色素沉着症基因的发现和分子基因检测的可用性极大地改变了人们对该疾病的生理病理、外显率和表达的认识,并对诊断环境产生了重大影响。涉及领域:血色素沉着症是一种遗传和表型水平的异质性疾病。本文讨论了确定患者铁表型的标准,以及使用分子检测诊断hfe相关和非hfe血色素沉着症。检查的材料包括发表在PubMed美国国家医学图书馆覆盖的期刊上的文章。作者在铁超载疾病领域工作多年,在参考文献中引用了18篇论文。专家意见:血色素沉着症基因分型与表型表征是分不开的。当数据明确显示怀疑有HH风险时,需要进行全面的临床评估和DNA检测。HFE检测p.Cys282Tyr突变和p.c his63asp突变是分子诊断的第一步。罕见突变的基因分型可提供给一级HFE检测阴性且铁超载无其他解释的患者,应在铁超载疾病的转诊中心进行,这些转诊中心可以提供遗传建议和内部基因分型服务。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Simtomax, a novel point of care test for coeliac disease. Diagnosis of skeletal muscle channelopathies. Review of latent and lytic phase biomarkers in Kaposi's sarcoma. The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. Novel diagnostic and prognostic biomarkers in esophageal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1